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Antidepressant use during pregnancy and
risk of autism spectrum disorder and
attention deficit hyperactivity disorder:
systematic review of observational studies
and methodological considerations
Daniel R. Morales1,2* , Jim Slattery1, Stephen Evans3 and Xavier Kurz1
Abstract
Background: Antidepressant exposure during pregnancy has been associated with an increased risk of autism
spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in several observational studies. We
performed a systematic review of these studies to highlight the effect that important methodological limitations
have on such analyses and to consider approaches to the conduct, reporting and interpretation of future studies.
Methods: A review of MEDLINE and EMBASE identified case–control, cohort and sibling studies assessing the risk of
ASD and ADHD with antidepressant use during pregnancy. Approaches to confounding adjustment were described.
Crude and adjusted effect estimates for comparisons between antidepressant exposure during pregnancy vs. all
unexposed women were first meta-analysed using a generic inverse variance method of analysis, followed by effect
estimates for alternative pre-selected comparison groups.
Results: A total of 15 studies measuring ASD as an outcome (involving 3,585,686 children and 40,585 cases) and seven
studies measuring ADHD as an outcome (involving 2,765,723 patients and 52,313 cases) were identified. Variation in
confounding adjustment existed between studies. Updated effect estimates for the association between maternal
antidepressant exposure during pregnancy vs. all unexposed women remained statistically significant for ASD (adjusted
random-effects risk ratio [RaRR] 1.53, 95% confidence interval [CI] 1.31–1.78). Similar significant associations were
observed using pre-pregnancy maternal antidepressant exposure (RaRR 1.48, 95% CI 1.29–1.71) and paternal
antidepressant exposure during pregnancy (1.29, 95% CI 1.08–1.53), but analyses restricted to using women with a
history of affective disorder (1.18, 95% CI 0.91–1.52) and sibling studies (0.96, 95% CI 0.65–1.42) were not statistically
significant. Corresponding associations for risk of ADHD with exposure were: RaRR 1.38, 95% CI 1.13–1.69 (during
pregnancy), RaRR 1.38, 95% CI 1.14–1.69 (during pre-pregnancy), RaRR 1.71, 95% CI 1.31–2.23 (paternal exposure), RaRR
0.98, 95% CI 0.77–1.24 (women with a history of affective disorder) and RaRR 0.88, 95% CI 0.70–1.11 (sibling studies).
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Conclusions: Existing observational studies measuring the risk of ASD and ADHD with antidepressant exposure are
heterogeneous in their design. Classical comparisons between exposed and unexposed women during pregnancy are
at high risk of residual confounding. Alternative comparisons and sibling designs may aid the interpretation of causality
and their utility requires further evaluation, including understanding potential limitations of undertaking meta-analyses
with such data.
Keywords: Autism, Attention Deficit Hyperactivity Disorder, Pregnancy, Antidepressant, Meta-analysis, Epidemiology
Background
The safety of medicines during pregnancy and their
effect on foetal development is an important concern for
public health and medicines regulatory agencies world-
wide. Clinical drug safety trials in pregnant women are
usually infeasible or unethical to perform. Therefore,
evidence from observational studies is relied upon to
evaluate the safety of medicines used during pregnancy
to inform regulatory decision-making and assess the
need for risk-minimisation measures.
Childhood neurodevelopmental disorders are a group
of conditions with onset in the developmental period,
often before children reach school age. In the Diagnostic
and Statistical Manual of Mental Disorders 5 (DSM-5),
neurodevelopmental disorders are organised into seven
subcategories: intellectual disabilities, communication
disorders, autism spectrum disorder (ASD), attention
deficit hyperactivity disorder (ADHD), specific learning
disorders, motor disorders and other neurodevelopmen-
tal disorders (those disorders having symptoms consist-
ent with, but which fail to meet full diagnostic criteria
for, any disorder in the neurodevelopmental disorder
diagnostic class) [1]. Potential risk factors for neurodeve-
lopmental disorders include male sex, genetic influences,
health behaviours associated with socioeconomic charac-
teristics (such as abuse of alcohol or use of recreational
drugs), parental mental health disorders, toxin exposure,
obesity, and prenatal and delivery complications [2–4].
However, these disorders often encompass a spectrum of
presentations, and there are likely to be potentially
unknown environmental or genetic risk factors. Partly
because of this spectrum, the definition will depend on
the age at assessment and it is very difficult to standard-
ise within and between studies. It is certainly not a sim-
ple ‘yes/no’ binary outcome.
The incidence of neurodevelopmental disorders such
as ASD and ADHD is reported to have increased in re-
cent decades, the reasons for which are uncertain [2, 5].
This may in part be related to changing diagnostic and
coding practices but the effects of maternal exposure to
medicines during pregnancy has also been proposed [6].
In Europe, between 3% and 17% of women reportedly
experience depression during pregnancy [7–10] and
antidepressants are one of the most commonly used
medicines in pregnancy [11–13]. In a study of selective
serotonin reuptake inhibitor (SSRI) exposure before,
during and after pregnancy in six European regions, the
prevalence of SSRI exposure at any point during preg-
nancy ranged between 1.2% and 4.5% [14]. This was
highest in the UK and increased between 2004 and 2010.
Observational studies evaluating the safety of anti-
depressant exposure during pregnancy face important
challenges. These include: confounding by indication
(where the indication for exposure is directly linked to
the risk of health outcomes), difficulties in adjusting for
the severity of disease (women with severe symptoms
are more likely to be prescribed a medicine during preg-
nancy where the perceived benefit of treatment may be
greater than those with less severe symptoms), assessing
antidepressant exposure as a class effect when recom-
mendations for the choice of antidepressants may vary
between countries [14] and differences in data sources
in terms of completeness and accuracy of information
on exposure, outcome, confounders and family history
of relevant genetic disorders. Studies using alternative
antidepressants as the comparator may be less subject to
confounding than those which use unexposed mothers.
Several observational studies have investigated the as-
sociation between maternal antidepressant exposure
during pregnancy and the risk of neurodevelopmental
outcomes, which has resulted in the first meta-analysis
of observational studies by Man et al. describing a sig-
nificantly increased risk of ASD in children exposed in
utero to SSRIs [15]. Some observational studies included
in that report contained a number of important limita-
tions inherent in this type of research, including those
described above that raise questions as to the value of a
meta-analytical approach. Furthermore, additional obser-
vational studies have since emerged that may cause
significant public concern [16–19].
In September 2016, the Pharmacovigilance Risk
Assessment Committee (PRAC) of the European Medicines
Agency (EMA) concluded that the current evidence does
not support a causal association and that the available
studies on the risk of ASD after in utero exposure to SSRIs
are conflicting, in part due to the different study designs
and study populations chosen for analysis [20]. The aim of
this study was to perform a systematic review of
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observational studies examining the risk of ASD and
ADHD associated with maternal antidepressant exposure
during pregnancy and, supporting this, to highlight their
methodological limitations and to consider approaches to
the conduct, reporting and interpretation of studies investi-
gating antidepressant exposure during pregnancy and risk
of neurodevelopmental outcomes. The limitations of trying
to obtain a single answer using meta-analysis are also con-
sidered. This article does not discuss the conclusion of the
PRAC.
Methods
A systematic review of MEDLINE and EMBASE was
performed using a pre-specified search strategy to iden-
tify all case–control, cohort or sibling studies published
on or before May 2017 evaluating the risk of ASD and
ADHD following antidepressant exposure during
pregnancy. The search strategy consisted of the follow-
ing search terms: (SSRI* OR serotonin uptake inhibitor
OR antidepressant* OR fluoxetine OR citalopram OR
escitalopram OR paroxetine OR sertraline OR venlafax-
ine OR trazodone OR mirtazapine OR duloxetine OR
amitriptyline OR nortriptyline OR imipramine OR
fluvoxamine OR nefazadone) AND (pregnancy OR preg-
nant OR prenatal) AND (autism OR autistic OR perva-
sive developmental disorder OR ASD OR ADHD OR
attention deficit). Titles and abstracts were screened and
full texts of relevant articles assessed for eligibility. Only
English-language publications and published data were
included. A cumulative review of available data (for
example, pharmacoepidemiological studies and the
published literature) submitted to the EMA by mar-
keting authorisation holders of all SSRI drugs follow-
ing a request by the PRAC in 2016 was screened to
identify additional studies. Methodological quality and
risk of bias for the main comparison between exposed
vs. unexposed women during pregnancy were evalu-
ated for each study using the ROBINS-I tool, includ-
ing misclassification of exposure, misclassification of
outcome and selection bias [21]. The ROBINS-I tool
is designed to assess the strengths and weaknesses of
non-randomised studies on the effects of interven-
tions in terms of their risk of bias. The tool views
each study as an attempt to mimic a hypothetical
pragmatic randomised trial, and covers seven distinct
domains through which bias might be introduced:
confounding, selection or participants into the study,
classification of interventions, deviations due to
intended interventions, missing data, measurement of
outcome measures and selection of the reported result.
The systematic review was registered on the EU Register
of Post-Authorisation Studies (EUPAS18909) and reported
according to PRISMA (Preferred Reporting Items for
Systematic Reviews) [22].
Data extraction
Part of the difficulty in interpreting the results from
existing studies can relate to confounding by indication
whereby the indication for treatment is itself associated
with the risk of future health outcomes. Attempts to cir-
cumvent the problems of confounding by indication
potentially include using different comparator or refer-
ence groups for analysis (for example, using alternative
antidepressants as the comparator) and different study
designs. For this reason, data from included studies were
extracted for the following characteristics: study design,
sample size, type of comparator or reference group
reported, and the accuracy and completeness of informa-
tion on confounders (including the severity of depres-
sion, indication for treatment, lifestyle factors, use of
co-prescribed medication, maternal age at conception
and family history). For each comparison, crude and
adjusted effect estimates (odds ratios, hazard ratios and
rate ratios) were identified with corresponding 95% con-
fidence intervals (CIs). For some studies, only the ad-
justed effect estimates were available. The outcomes of
interest were the risk of ASD and ADHD in children fol-
lowing antidepressant exposure during pregnancy.
Comparators, reference groups and sibling study design
To examine the impact of using different comparator or
reference groups in causal inference, effect estimates for
the following pre-specified antidepressant comparator or
reference groups were extracted: (1) maternal exposure
during pregnancy vs. all unexposed women (we refer to
this as the classical comparison), (2) maternal exposure
during the pre-pregnancy period vs. all unexposed
women (this exposure should theoretically be non-causal
and may act as a negative control), (3) maternal
exposure during pregnancy vs. all unexposed women re-
stricted to those with a history of affective disorder (such
as depression, anxiety and bipolar disorder) (the restric-
tion may remove some confounding by indication or
severity in that the indication for treatment is independ-
ently associated with ASD/ADHD, for example, through
genetics), (4) paternal exposure during the maternal
pregnancy period vs. all unexposed women (this expos-
ure should theoretically be non-causal and may act as a
negative control) and (5) effect estimates from within-
family sibling analyses (which accounts for all time-fixed
within-family confounding). Exposure windows were as
defined by the eligible studies.
Analysis
The characteristics of the studies included and hetero-
geneity in confounding adjustment were first described.
Effect estimates from each study were then used to re-
produce the results from the meta-analysis by Man et al.
and to assess the effect of adding effect estimates from
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additional published studies that reported associations
using a classical reference group consisting of all
unexposed women [15]. Crude and adjusted effect esti-
mates were calculated on the natural log scale and
pooled using the generic inverse variance method of
analysis. Random-effects models were generated with
fixed-effect models as the sensitivity analysis. This
approach was then used to explore the pre-specified
comparisons or reference groups that were compared to
those from the classical reference group. Studies pub-
lished using the same national data sources and patients
were included separately and effect estimates generated
with each separate study included as a sensitivity
analysis. A leave-one-out analysis was also conducted
when three or more studies were pooled to test the ro-
bustness of the analysis.
Odds ratios from case–control studies and hazard ra-
tios from cohort studies were combined because they
closely approximate each other, with sensitivity analyses
performed by study design to assess for heterogeneity
[23, 24]. Effect estimates were pooled by trimester of ex-
posure where this information was available. When
estimates for SSRI exposure and any antidepressant
exposure were each reported within the same study,
the effect estimate for SSRI exposure was preferen-
tially used because it is the most widely used group
of antidepressants, with sensitivity analysis performed
using estimates for any antidepressant exposure. For
reporting, pooled effect estimates are subsequently re-
ferred to as risk ratios throughout. Analyses were
conducted in Review Manager 5.3 (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collabor-
ation, 2014). Publication bias was assessed by testing
for funnel-plot asymmetry using the Egger test for
studies reporting results of the classical reference
group with ASD and ADHD.
Results
This systematic review identified 464 articles (111 articles
from MEDLINE and 353 articles from EMBASE).
Autism spectrum disorder
Following the removal of duplicates and screening of
remaining articles, there was a total of 15 observational
studies measuring ASD as an outcome [16–19, 25–35].
No additional studies were identified from the cumula-
tive review requested by the PRAC and submitted by the
marketing authorisation holders of SSRIs. Characteristics
of the included studies are presented in Table 1. For
ASD as the outcome, seven case–control studies (involv-
ing 291,468 patients and 13,243 cases of ASD) [17, 18,
26–29, 32] and eight cohort studies (involving 3,294,218
patients and 27,342 cases of ASD) [16, 19, 25, 30, 31,
33–35] were included.
Of the 15 observational studies measuring ASD as
the outcome, all reported adjusted effect estimates for
the comparison between maternal antidepressant ex-
posure during pregnancy vs. all unexposed women
(nine of which reported effect estimates by trimester).
Eight observational studies reported adjusted effect
estimates for maternal antidepressant exposure during
the pre-pregnancy period vs. all unexposed women.
Seven observational studies reported adjusted effect
estimates for maternal antidepressant exposure during
pregnancy vs. all unexposed women with a past
medical history of affective disorder. Three observa-
tional studies reported results from a sibling analysis
[25, 33, 35] and two observational studies reported
results for paternal antidepressant exposure during
the maternal pregnancy period vs. all unexposed
women [33, 34] (Additional file 1: Table S1).
Attention deficit hyperactivity disorder
Following the removal of duplicates and screening of
remaining articles, a total of seven observational studies
measuring ADHD as an outcome [17, 18, 31, 34, 36–38]
were identified (Fig. 1). For ADHD as the outcome, three
case–control studies (involving 51,944 patients and 4,375
cases of ADHD) [17, 18, 36] and four cohort studies (in-
volving 2,713,779 patients and 51,938 cases of ADHD)
[31, 33, 37, 38] were included. Of the seven included ob-
servational studies measuring ADHD as the outcome, all
reported adjusted effect estimates for the association be-
tween maternal antidepressant exposure during pregnancy
vs. all unexposed women (of which six reported effect esti-
mates by trimester). Five observational studies reported
adjusted effect estimates for maternal antidepressant ex-
posure during the pre-pregnancy period vs. all unexposed
women. One observational study reported effect estimates
for maternal antidepressant exposure during pregnancy
vs. unexposed women with a past medical history of
affective disorder [31]. Three observational studies
reported results from sibling analyses [34, 37, 38] and one
study reported estimates for paternal antidepressant ex-
posure during pregnancy [34] (Additional file 1: Table S1).
Confounding factors assessed by the included observational
studies
For ASD as an outcome, all studies evaluated the impact
of maternal age and maternal psychiatric history (Table 2).
Most studies evaluated sex of the offspring, year of birth,
gestational age, birth weight, educational attainment, eth-
nicity or country of origin, and parity. Adjustment for use
of other medicines during pregnancy occurred in five
studies assessing ASD as the outcome and four studies
assessing ADHD as the outcome [19, 25, 31, 34–37].
However, the definition of exposure to the use of other
medicines during pregnancy focused on the use of other
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psychotropic drugs [35, 36, 38], use of anxiolytics and sed-
atives [19, 31, 37] or use of nicotine products [29], with
only one study accounting for all types of medications
used [25]. Adjustment for paternal psychiatric history,
maternal physical history, complications in pregnancy,
smoking status, and alcohol or other substance misuse oc-
curred less often. The severity of depression was evaluated
in only four studies and was limited either to measures of
maternal treatment intensity in terms of number of anti-
depressant and psychotherapy visits [17, 18] or to use of a
validated self-reported questionnaire [19], and by applying
high-dimensional propensity scores [25]. Similar distribu-
tions were seen for ADHD as an outcome (Table 3). None
of the included studies adjusted for the recurrent nature
Table 1 Characteristics of included observational studies measuring risk of ASD and ADHD with antidepressant exposure in pregnancy
Study [Reference] Primary study design Number of children Number of cases Case definition Data source, country (period)
Autism spectrum disorder
Boukhris 2015 [16] Cohort 145,456 1054 ICD-9, ICD-10 Quebec pregnancy children’s cohort,
Canada (1998–2009)
Brown 2017 [23] Cohort 35,906 394 ICD-9, ICD-10 Administrative databases, Ontario,
Canada (2002–2010)
Castro 2016 [17] Case–control 4650 1245 ICD-9 Massachusetts General Hospital,
USA (1997–2010)
Clements 2015 [18] Case–control 5399 1377 ICD-9 Massachusetts General Hospital,
USAa (1997–2010)
Croen 2011 [24] Case–control 1805 298 ICD-9 Kaiser Permanente, USA (1995–1999)
El Marroun 2014 [19] Cohort 5976 Not reported *CBCL 1.5–5, SRS Generation R study, Netherlands
(2002–2006)
Eriksson 2012 [25] Case–control 173,577 187 Clinical diagnosis Stockholm, Sweden (2002–2006)
Gidaya 2014 [26] Case–control 57,365 5215 ICD-10 Danish Civil Registration System,
Denmark (1996–2006)
Harrington 2014 [27] Case–control 966 492 ADI-R/ADOS Charge study, USA (2003–2010)
Hviid 2013 [28] Cohort 626,875 3892 ICD-10 Danish Civil Registration System,
Denmark (1997–2005)
Malm 2016 [29] Cohort 64,754 307 ICD-10 National registers, Finland (1996–2010)
Rai 2013 [30] Case–control 47,706 4429 ICD-9, ICD-10 Regional administrative registries,
Sweden (2001–2007)
Sorensen 2013 [31] Cohort 655,615 5437 ICD-8, ICD-10 Danish Civil Registration System,
Denmark (1996–2006)
Sujan 2017 [32] Cohort 1,580,629 14,617 ICD-9, ICD-10 National administrative registries,
Sweden (1996–2012)
Viktorin 2017 [33] Cohort 179,007 1641 ICD-10 National administrative registries,
Sweden (2006–2007)
Attention deficit hyperactivity disorder
Castro 2016 [17] Case–control 5498 1701 ICD-9 Massachusetts General Hospital,
USA (1997–2010)
Clements 2015 [18] Case–control 7874 2243 ICD-9 Massachusetts General Hospital,
USAa (1997–2010)
Figueroa 2010 [34] Case–control 38,572 431 ICD-9 Marketscan, USA (1997–2006)
Laugesen 2013 [35] Cohort 877,778 12,841 ICD-8, ICD-10 Danish Civil Registration System,
Denmark (1996–2009)
Malm 2016 [29] Cohort 64,754 514 ICD-10 National registers, Finland (1996–2010)
Man 2017 [36] Cohort 190,618 5659 ICD-9 Clinical Data Analysis & Reporting
System, Hong Kong (2001–2009)
Sujan 2017 [32] Cohort 1,580,629 32,924 ICD-9, ICD-10 National administrative registries,
Sweden (1996–2012)
*Parent-reported autistic symptoms assessed using: CBCL 1.5–5, the pervasive developmental problems subscale of the Child Behaviour Checklist for ages 1.5–5,
and SRS, the Social Responsiveness Scale
“Clinical diagnosis” indicates receiving intervention for ASD at a specialised Autism Centre for Young Children
ADI-R Autism Diagnostic Interview, Revised, ADOS Autism Diagnostic Observation Schedule, ICD International Classification of Disease coding system
aNew, independent cohort
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or the duration of depression, and no studies used diagno-
ses recorded in primary care, potentially leading to under-
ascertainment of depression history.
Impact of meta-analysing effect estimates
Autism spectrum disorder The meta-analysis by Man
et al. demonstrating that maternal SSRI exposure during
pregnancy was associated with a significantly increased
risk of ASD in children vs. all unexposed women was
successfully replicated (Additional file 2: Figure S1) [15].
Effect estimates were then calculated incorporating data
from the classical reference group consisting of all
unexposed women using additional published articles on
antidepressant use during pregnancy. Following inclu-
sion of these data, the risk of ASD with maternal anti-
depressant exposure during pregnancy vs. all unexposed
women still appeared statistically significantly increased
(random-effects adjusted risk ratio [RaRR] 1.53, 95% CI
1.31–1.78, Table 4 and Fig. 2). When evaluated by tri-
mester of pregnancy, the risk of ASD in children with
maternal antidepressant exposure during pregnancy
vs. all unexposed women was statistically significantly
elevated in the first and second trimesters only
(Additional file 3: Figure S2).
Pooled effect estimates for the risk of ASD among differ-
ent comparator groups are summarised in Table 4. The
risk of ASD associated with maternal antidepressant ex-
posure during the pre-pregnancy period vs. all unex-
posed women appeared statistically significantly elevated
(RaRR 1.48, 95% CI 1.29–1.71, Fig. 3) and was similar in
size to that of exposure during pregnancy. Pooled effect
estimates for the risk of ASD associated with maternal
antidepressant exposure during pregnancy compared to
unexposed women with a history of affective disorder
did not appear to be statistically significantly increased
(RaRR 1.18, 95% CI 0.91–1.52, Fig. 4). The effect
estimate for the risk of ASD associated with maternal
antidepressant exposure during pregnancy reported by
three within-family sibling studies did not suggest an in-
crease in risk (RaRR 0.96, 95% CI 0.65–1.42). In con-
trast, the effect estimate for the risk of ASD associated
with paternal antidepressant exposure during the mater-
nal pregnancy period vs. all unexposed women two
studies showed a statistically significantly increased risk
(RaRR 1.29, 95% CI 1.08–1.53).
Fig. 1 PRISMA (Preferred Reporting Items for Systematic Reviews) flow diagram for study selection. ADHD attention deficit hyperactivity disorder,
ASD autism spectrum disorder
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Table 3 Potential confounders and risk factors evaluated in studies of maternal antidepressant use during pregnancy and risk of
attention deficit hyperactivity disorder in offspring
Potential confounder Castro 2016 Clements 2015 Figueroa 2010 Laugesen 2013 Malm 2016 Man 2017 Sujan 2017
Reference 17 18 34 35 29 36 32
Gender Y Y Y Y Y Y –
Year of birth Y Y Y – Y Y Y
Birth weight – Y Y Y Y Y –
Gestational age at delivery Y Y Y Y Y Y –
Maternal age Y Y Y Y Y Y Y
Marital status – – – Y Y – –
Living alone – – – – – – –
Education Y Y – – – – Y
Social assistance or economic status – – – – – Y –
Maternal psychiatric historya Y Y Y Y Y Y Y
Paternal psychiatric historya – – – Y – – –
Maternal physical historyb – Y Y Y Y Y –
Pregnancy or delivery complications – Y Y – Y – –
Paternal physical history – – Y – – – –
Severity of depression Y Y – – – – –
Smoking status – – – Y Y – –
Alcohol or substance misuse – – – – Y – –
Parity Y Y – Y Y Y Y
Insurance type Y Y – – – – –
Ethnicity or country of origin Y Y – – Y – Y
Maternal income Y – – – – – –
Residence – – Y – Y – –
Employment status – – – – Y – –
Depression recurrence – – – – – – –
Drugs other than antidepressantsc – – Y Y Y Y –
aHeterogeneity in definitions used
bIncludes only a limited number of physical conditions, such as diabetes, hypertension and autoimmune disease, and varies by study
cIncludes only a limited number of other drugs used during pregnancy and varies by study (benzodiazepines, antipsychotics, teratogens etc.)
Table 4 Pooled crude and adjusted effect estimates for the different comparator and reference groups in included observational
studies measuring the association between antidepressant exposure and risk of autism spectrum disorder (random-effects model)
Comparison Crude RR No. of studies Adjusted risk ratio No. of studies
Maternal exposure during pregnancy vs. unexposed women 1.85 (1.60–2.23) 10 1.53 (1.31–1.78) 10
Maternal exposure pre-pregnancy vs. unexposed women 1.71 (1.42–2.05) 6 1.48 (1.29–1.71) 7
Maternal exposure during pregnancy vs. unexposed
women with a history of affective disorder
1.35 (0.75–2.44) 3 1.18 (0.91–1.52) 6
Sibling study design 1.01 (0.48–2.14) 2 0.96 (0.65–1.42) 3
Paternal exposure during the maternal pregnancy period
vs. unexposed women
1.40 (1.10–1.80) 1 1.29 (1.08–1.53) 2
Not all studies reported crude effect estimates explaining the difference in the number of studies. Pooled effect estimates are presented when reported by two or
more studies
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Attention deficit hyperactivity disorder Effect esti-
mates for the risk of ADHD among the different com-
parator groups are summarised in Table 5. The risk of
ADHD with maternal antidepressant exposure during
pregnancy using a classical reference group consisting of
all unexposed women appeared to be statistically signifi-
cantly increased (RaRR 1.38, 95% CI 1.13–1.69, Fig. 5).
When evaluated by trimester of pregnancy, the risk of
ADHD in children with maternal antidepressant expos-
ure during pregnancy vs. all unexposed women was sta-
tistically significantly elevated in the first and second
trimesters only using a random effect model (Additional
file 4: Figure S3). The risk of ADHD associated with
maternal antidepressant exposure during the pre-
pregnancy period vs. all unexposed women was similarly
statistically significantly elevated (RaRR 1.38, 95% CI
1.14–1.69, Fig. 6) and was similar in size to exposure
during pregnancy.
The risk of ADHD associated with maternal anti-
depressant exposure during pregnancy vs. all unexposed
women with a history of affective disorder from only a
single cohort study suggested no significant association
(RaRR 0.98, 95% CI 0.77–1.24). The effect estimate for
the risk of ADHD associated with maternal antidepressant
exposure during pregnancy reported in three within-
family sibling studies suggested no significant association
(RaRR 0.88, 95% CI 0.70–1.11, Fig. 7). A single
observational study measuring the risk of ADHD associ-
ated with paternal antidepressant exposure during the ma-
ternal pregnancy period vs. all unexposed women was also
statistically significant (RaRR 1.71, 95% CI 1.31–2.23).
Sensitivity analyses The observed pattern of effect
estimates for the other comparison and reference groups
and sibling designs were similar when analysed using a
fixed-effect model, although the association was significant
in all trimesters for ASD and ADHD (Additional file 1:
Table S2 and S3, Additional file 7: Fig. S4 and Additional
file 8: Fig. S5).. Three studies used the same data source
and related patients from Denmark [28, 30, 33] and three
from Sweden [32, 34, 35]. The relative size of effect esti-
mates between the different comparator groups was similar
when studies with overlapping data from each country were
substituted (Additional file 1: Table S4). Substituting the
effect estimates for any antidepressant exposure from stud-
ies reporting estimates for both SSRI exposure and any
antidepressant exposure produced very similar results
(Additional file 1: Table S5). The risk of ASD and ADHD
with maternal antidepressant exposure during pregnancy
vs. all unexposed women and the observed pattern of effect
estimates between different comparison and reference
groups appeared similar across study designs (Additional
file 1: Tables S6 and S7, Additional file 5: Figure S6 and
Fig. 2 Risk of autism spectrum disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women. CI
confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 3 Risk of autism spectrum disorder associated with pre-pregnancy maternal antidepressant exposure during pregnancy compared to unexposed
women. CI confidence interval, df degrees of freedom, SE standard error of the mean
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Additional file 6: Figure S7). Results from a leave-one-out
analysis were consistent with the main findings.
Risk of bias
Of the 15 studies assessing ASD as an outcome, 11 studies
were considered to be at moderate risk of bias for the clas-
sical comparison between exposed and unexposed women
and four studies at serious risk of bias (Additional file 1:
Table S8). Of the five studies assessing ADHD as an out-
come, all were considered to be at moderate risk of bias
for the classical comparison between exposed and unex-
posed women (Additional file 1: Table S9). Specific areas
judged to be affected related to: bias due to deviations
from intended interventions (bias that arises when there
are systematic differences between experimental interven-
tion and comparator groups in the care provided, which
represents a deviation from the intended intervention),
bias due to baseline confounding and bias due to missing
data. Pregnancy exposure windows were well defined in
all studies although it was not possible to determine what
proportion of patients with pre-pregnancy exposure con-
tinued antidepressant exposure during pregnancy. No evi-
dence of publication bias was detected when testing for
funnel-plot asymmetry using the Egger test for either ASD
(p value = 0.433) or ADHD (p value = 0.901).
Discussion
This systematic review was performed to evaluate the
content of published observational studies investigating
the association between antidepressant exposure during
pregnancy and risk of ASD and ADHD in offspring.
These studies can be difficult to interpret due to limita-
tions in unmeasured confounding, particularly in rela-
tion to confounding by indication and the severity of
depression, inherent in this type of research. We also
evaluated which effect estimates associated with different
comparator or reference groups have been reported and
their potential for helping to interpret the results of such
studies including pre-pregnancy exposure, restriction to
women with a history of psychiatric illness, paternal
exposure and sibling designs. Taken together, these re-
sults suggest that the significant associations observed
using a classical reference group comparing risk among
all unexposed women result from residual unmeasured
confounding.
Variation in the type of confounding adjustment
undertaken between observational studies existed, which
may lead to heterogeneity and the risk of residual
confounding. This partly relates to the limitations of cur-
rently available data sources for studying such effects
and environmental and genetic influences. These are
important factors when considering the limitations of
undertaking potential meta-analyses with these data, as
simply adding more results from similarly designed stud-
ies is unlikely to remove the problems of confounding
and bias, but risks misleading by giving the appearance
of better precision.
We reproduced data from an early meta-analysis that
reported a significant association between maternal SSRI
exposure during pregnancy and risk of ASD in offspring,
Fig. 4 Risk of autism spectrum disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed women
with a history of affective disorder. CI confidence interval, df degrees of freedom, SE standard error of the mean
Table 5 Pooled crude and adjusted effect estimates for the different comparator and reference groups in included observational
studies measuring the association between antidepressant exposure and risk of attention deficit hyperactivity disorder (random-effects)
Comparison Crude risk ratio No. of studies Adjusted risk ratio No. of studies
Maternal exposure during pregnancy vs. unexposed women 2.04 (1.62–2.56) 5 1.38 (1.13–1.69) 7
Maternal exposure pre-pregnancy vs. unexposed women 1.42 (1.09–1.84) 2 1.38 (1.14–1.69) 5
Maternal exposure during pregnancy vs. unexposed women
with a history of affective disorder
1.01 (0.80–1.27) 1 0.98 (0.77–1.24) 1
Sibling design 0.8 (0.5 to 1.2) 1 0.88 (0.70–1.11) 3
Paternal exposure during the maternal pregnancy period vs. unexposed women – 0 1.71 (1.31–2.23) 1
Not all studies reported crude effect estimates explaining the difference in the number of studies. Pooled effect estimates are presented when reported by two or
more studies
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observed when a classical reference group was used (de-
fined purely by the absence of SSRI exposure in women)
[15]. When this meta-analysis was updated with further
published data, antidepressant exposure during preg-
nancy still appeared to be associated with a significantly
increased risk of ASD in offspring when exposed women
were compared to all unexposed women. However, the
size of the association was more attenuated, falling from
an association suggesting an 80% increased risk of ASD
to an association suggesting a 53% increased risk. This
supports our statement that simply adding more results
from studies with similar limitations is unlikely to
remove the problem of residual confounding. Women
included in the classical reference group are more likely
to be healthy, without a history of affective disorder and
the social, environmental and genetic factors associated
with these. Such comparisons are at high risk of con-
founding by indication and severity of illness, and it is
difficult to determine with confidence whether associa-
tions from this type of comparison alone are causal
because many factors remain unmeasured. Similarly,
we observed an association suggesting a 38% in-
creased risk of ADHD with antidepressant exposure
during pregnancy.
We then examined which effect estimates had been re-
ported using different reference groups where exposure
may or may not theoretically cause ASD or ADHD, and
then examined the effect of pooling these estimates be-
tween studies. The most commonly reported alternative
comparison was for pre-pregnancy exposure. For both
ASD and ADHD as an outcome, the size of effect
estimates for antidepressant exposure during pre-
pregnancy were comparable to that observed for expos-
ure during pregnancy using the classical reference group
consisting of all unexposed women. Additionally, paternal
exposure during the maternal pregnancy period was also
associated with an increased risk of ASD and ADHD in
offspring, although this was less frequently assessed. The
next commonly reported comparison involved restricting
the comparator group to women with a history of affective
disorder, in an attempt to circumvent unmeasured con-
founding and confounding by indication by design. These
effect estimates appeared to be non-significant for
both ASD and ADHD. Finally, sibling studies are a
type of within person (mother) design that can cir-
cumvent fixed confounding and some confounding by
indication, which may affect between-person compari-
sons. These sibling studies found no statistically sig-
nificant association with ASD or ADHD.
A systematic review by Brown et al. was recently pub-
lished focusing specifically on the risk of ASD from SSRI
exposure in pregnancy and provides complimentary
information [39]. Brown et al. examined the impact of
studies adjusting for current and past psychiatric history,
and the impact of restricting the population to women
with a history of psychiatric illness. They combined
these data using fixed and random-effects models. The
quality of the included observational studies was
assessed using the SAQOR quality rating scale, a tool
that also attempts to capture confounding by indication
[40]. Assessing quality using this separate approach,
Brown et al. similarly noted that none of the included
Fig. 5 Risk of attention deficit hyperactivity disorder associated with maternal antidepressant exposure during pregnancy compared to unexposed
women. CI confidence interval, df degrees of freedom, SE standard error of the mean
Fig. 6 Risk of attention deficit hyperactivity disorder associated with pre-pregnancy maternal antidepressant exposure during pregnancy compared to
unexposed women. CI confidence interval, df degrees of freedom, SE standard error of the mean
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case–control studies met the criteria for adequate
consideration of distorting influences. We used the
recently developed ROBINs-I tool to assess the risk
of bias of the included observational studies, and
noted similar issues. To our knowledge there are no
head-to-head comparisons between these different
quality assessment tools to determine which is best.
However, consistency in results using different tools
may help to provide independent validation of the
conclusions of both studies on this topic.
Brown et al. similarly noted the increased association
between SSRI exposure in pregnancy compared to all
unexposed women, even following an adjustment for a
history of psychiatric illness, which suggests that current
approaches that simply rely upon confounding adjust-
ment between these populations is insufficient. However,
only two studies examining the impact of restriction of
the population were available, both of which were non-
significant. The potential for under-identification of
maternal illness was also noted, because diagnoses were
defined using administrative databases only. As in our
analysis, in many instances these diagnoses are hospital
based and probably more at the severe end of the
spectrum, which may partly explain the observed pattern
of results seen in our study.
Limitations of the studies reviewed and the
methodological approach
While there is a temptation to obtain a single result from
combining the results of studies, the methods used for
combining them treat them in the same way as if the data
had come from randomised trials. The uncertainty in esti-
mates derived from observational studies is potentially
greater than the sampling error that is captured by a con-
fidence interval and may be related to heterogeneity, such
as variation in confounding adjustment undertaken be-
tween studies. It is perhaps a matter of debate as to
whether such studies should routinely be meta-analysed
and if so which type of model or comparisons should be
used. For example, although the I2 statistic is often re-
ported in meta-analyses as a way of detecting heterogen-
eity, it is not an absolute measure of heterogeneity and
does not communicate the predicted range of effects [41].
Caution is generally required when combining esti-
mates from case–control and cohort studies in a meta-
analysis because this may be an important source of
heterogeneity [42]. The dominant issue influencing both
study designs is unmeasured confounding, largely
weighted by confounding indication and by severity of
disease. This affects case–control and cohort studies
similarly but the technique allows more studies to be
combined to highlight the observed effect, in keeping
with other similar results comparing these study designs
[43]. A strength of our study is the inclusion of a large
number of studies incorporating other types of compara-
tors and designs, comparing the effects in both ASD and
ADHD. However, for some alternative comparison
groups, only a limited number of effect estimates were
identified, such as paternal antidepressant exposure dur-
ing the maternal pregnancy period, and their potential
utility requires further evaluation, although the sibling
design has good potential.
General limitations with most of the observational
studies included in this systematic review include incom-
plete ascertainment of psychiatric history (i.e. diagnoses
only managed in primary care) and inadequate adjust-
ment for the severity of psychiatric depression, which
may be related to the outcomes of interest. Outcomes
were also predominantly defined using electronic coding
within population health-care databases, which still
largely require to be validated. For example, ASD repre-
sents a spectrum of symptoms and diagnoses that may
not be fully captured using standard coding approaches
and may require the use of validated scales to assess a
more complete range of neurodevelopmental disorders.
This potentially increases the chance of outcome
misclassification and either underestimating or overesti-
mating risk. Accurate exposure assessment is also
required for such studies and it was not reported what
proportion of patients with pre-pregnancy exposure may
have continued antidepressant exposure during preg-
nancy. One observational study clearly reported in the
definition of pre-pregnancy exposure that the partici-
pants were subsequently unexposed during pregnancy
and the reported effect estimate for the association be-
tween pre-pregnancy exposure and risk of ASD was still
statistically significantly elevated. Similarly, a correlation
Fig. 7 Risk of attention deficit hyperactivity disorder associated with maternal antidepressant exposure during pregnancy using a sibling study
design. CI confidence interval, df degrees of freedom, SE standard error of the mean
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may exist between paternal and maternal antidepressant
exposure during pregnancy.
Sample size limitations mean it is currently challen-
ging to conduct observational studies assessing the asso-
ciation between certain neurodevelopmental disorders
and certain antidepressants, particularly for individual
medicines where there are differences in the frequency
of use between countries [14]. Such analyses may require
the use of multiple population databases to improve
power and precision if existing limitations in study de-
sign and confounding adjustment can be overcome.
Most analyses failed to account for exposure to other
commonly used medicines and of those which did, only
limited types of exposure were evaluated. Further adjust-
ment for such medication use may help to provide infor-
mation related to severity of the underlying condition
and overall health status. Our search is limited by the
databases used, as we did not have access to the full
range potentially available. Lastly, another potential limi-
tation is that the authors of the studies included were
not contacted.
Conclusions
Existing observational studies measuring the association
between antidepressant exposure during pregnancy and
risk of ASD and ADHD in offspring are heterogeneous
in their design and method of analysis. Classical compar-
isons between exposed and all unexposed women are at
risk of residual confounding that is difficult to adjust for
fully with existing data sources. Other comparisons and
study designs, such as sibling studies, contribute import-
ant additional information. It is recommended that such
future studies should consider incorporating these types
of analysis routinely in the design. However, the limita-
tions of undertaking meta-analyses using such data and
the value of using other comparators, reference groups
and other study designs requires further methodological
exploration. This has important implications because
such observational findings may result in significant
public health concerns and media interest, with potential
consequences of cessation of antidepressant treatment
during pregnancy and its impact on both maternal and
child health, and in this regard the benefit risk should be
considered in terms of both mother and offspring.
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